Matthew Scaramozza Selected Research

PF-06700841

1/2020	Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
1/2018	The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew Scaramozza Research Topics

Disease

2	Inflammation (Inflammations) 01/2022 - 01/2020
2	Multiple Sclerosis 01/2021 - 03/2014
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2020 - 01/2018
1	Neoplasms (Cancer) 01/2013
1	Relapsing-Remitting Multiple Sclerosis 01/2013

Drug/Important Bio-Agent (IBA)

2	PF-06700841IBA 01/2020 - 01/2018
2	Cladribine FDA LinkGeneric 03/2014 - 01/2013
1	BIIB091IBA 01/2021
1	Janus Kinase 1IBA 01/2020
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020
1	CytokinesIBA 01/2020
1	Interleukin-17 (Interleukin 17)IBA 01/2020
1	TabletsIBA 01/2013

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2021